Valeant Pharma (VRX) volatility at lower end of eight month range, Sequoia Fund exited position
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall, dragged by Alphabet and megacap tech; focus on Iran
- Oil falls almost 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
Valeant (VRX) Investors Should Be Focused on Earnings Not Upcoming Product Catalysts - Wells Fargo
July 14, 2016 1:29 PM EDTWhile Valeant Pharmaceuticals (NYSE: VRX) continues to avoid trading on fundamentals three potential catalysts lie ahead for the company. Today, Wells Fargo bearish-leaning analyst David Maris provide his thoughts ahead of these events.
The 3 events are:
Friday (7/15) advisory panel documents should become available ahead of next Tuesdays (7/19) FDA advisory panel on brodalumab;next... MoreRBC Highlights Next Week's Key Events for Valeant Pharma (VRX)
July 13, 2016 8:19 AM EDTRBC affirms Valeant Pharma (NYSE: VRX) at Sector Perform with a price target of $33 as the firm provides a schedule and commentary of what investors should focus on next week for the company.
RBC analyst Douglas Miehm noted:
Upcoming PDUFA dates: Oral Relistor (July 19) and latanoprostene bunod (July 21). Valeant has two PDUFA dates next week. The first, on July 19, is for Oral Relistor for the treatment of opioid-induced constipation. Following the FDA's delay in PDUFA date, we remain confident that Oral Relistor should see approval in or... MoreLong-Time Valeant Pharma (VRX) Holder Sequoia Fund Exits Position
July 13, 2016 6:09 AM EDTValeant Pharma (NYSE: VRX) shares are on watch Wednesday following news that long-time holder Sequoia Fund exited its position.
